Does PARP Inhibition Sensitize Chondrosarcoma Cell Lines to Chemotherapy or Radiotherapy? Results From a Three-dimensional Spheroid Cell Model
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Orthopaedics and Related Research"
DOI: 10.1097/corr.0000000000002483
Abstract: Abstract Background Chondrosarcomas are well known for their resistance to conventional chemotherapy and radiotherapy treatment regimens, which is particularly detrimental in patients who have unresectable tumors. Recently, inhibition of poly(ADP-ribose) polymerase (PARP) by talazoparib was… read more here.
Keywords: talazoparib; radiotherapy; chondrosarcoma; cell lines ... See more keywords
Abstract 4678: Pilot trial of talazoparib (BMN 673), an oral PARP inhibitor, in patients with advanced solid tumors carrying deleterious BRCA mutations
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-4678
Abstract: Inhibition of poly (ADP-ribose) polymerase (PARP) sensitizes tumor cells to DNA damage that would normally be repaired through the base excision repair pathway. PARP inhibitors are active clinically against BRCA-deficient ovarian cancers. The PARP inhibitor… read more here.
Keywords: trial; advanced solid; solid tumors; treatment ... See more keywords
Abstract 6186: Patient-derived tumor organoids with p53 mutations, and not wild-type p53, demonstrate synergistic sensitivity to treatment with temozolomide in combination with talazoparib PARP inhibitor
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-6186
Abstract: Mutations in the TP53 gene can be found in more than 50% of tumors. We recently showed in 2D breast cancer cell lines that mutant p53 (mtp53) proteins tightly associate with replicating DNA, chromatin and… read more here.
Keywords: mtp53; talazoparib; combination; p53 ... See more keywords
A preclinical trial to evaluate therapies for BRCA-associated pancreatic cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.4_suppl.332
Abstract: 332Background: Pancreatic ductal adenocarcinoma (PDAC) associated with germline BRCA1 or BRCA2mutations may have selective sensitivity to agents that exploit homologous recombination DNA repair defects. We hypothesized that cisplatin, a DNA-crosslinking agent, and talazoparib, a poly(ADP-ribose)… read more here.
Keywords: trial; trial evaluate; cisplatin; brca associated ... See more keywords
Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.3006
Abstract: 3006 Background: Talazoparib, a PARP inhibitor, is active in germline BRCA1/2 mutant advanced HER2-negative breast cancer, but its activity beyond BRCA1/2 is unknown. We conducted a single institution phase II trial to evaluate talazoparib in… read more here.
Keywords: breast cancer; brca1; talazoparib; breast ... See more keywords
Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany
Sign Up to like & getrecommendations! Published in 2022 at "PLOS ONE"
DOI: 10.1371/journal.pone.0278460
Abstract: This study evaluated factors that influence the cost-effectiveness of talazoparib, particularly for patients with a germline breast-cancer-gene-(brca)-mutation and locally advanced or metastasized breast cancer within the context of the German healthcare system. We constructed a… read more here.
Keywords: breast cancer; cost; talazoparib; cost effectiveness ... See more keywords
Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma
Sign Up to like & getrecommendations! Published in 2019 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2019.01416
Abstract: The Pediatric Preclinical Testing Program previously identified the PARP inhibitor talazoparib (TLZ) as a means to potentiate temozolomide (TMZ) activity for the treatment of Ewing sarcoma. However, the combination of TLZ and TMZ has been… read more here.
Keywords: combination; treatment; maximum tolerated; ewing sarcoma ... See more keywords
Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1158981
Abstract: PARP inhibitors are progressively becoming a part of our therapeutic arsenal against BRCA-defective tumors, because of their capacity to induce synthetic lethality in cells with a deficiency in the homologous recombination repair system. Olaparib and… read more here.
Keywords: talazoparib; breast cancer; response; cancer ... See more keywords
Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer
Sign Up to like & getrecommendations! Published in 2017 at "Theranostics"
DOI: 10.7150/thno.18563
Abstract: Talazoparib, a potent PARP inhibitor, has shown promising clinical and pre-clinical activity by inducing synthetic lethality in cancers with germline Brca1/2 mutations. Conventional oral delivery of Talazoparib is associated with significant off-target effects, therefore we… read more here.
Keywords: breast cancer; sustained release; brca1 deficient; talazoparib ... See more keywords